T-2143 / Tarveda Therap - LARVOL DELTA

Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors (Businesswire) - "Tarveda Therapeutics®, Inc...announced the publication of its preclinical study evaluating its HSP90 binding miniature drug conjugate with a pan-PI3K payload, T-2143, in solid tumors....'The results of the study published today confirm that T-2143 had superior efficacy to a non-targeted pan-PI3K inhibitor alone in a pre-clinical xenograft model, and that the tumor targeting and payload masking successfully reduced hyperglycemia, one of the most common dose-limiting toxicities in this class.'"

Preclinical • Oncology • Solid Tumor